Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05280314 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

A Phase 2 study of Melanoma and Squamous Cell Carcinoma of Head and Neck, sponsored by IO Biotech.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
15
Study locations

NCT05280314 is a Phase 2 study of Melanoma and Squamous Cell Carcinoma of Head and Neck that is actively recruiting participants, run by IO Biotech. The registered enrollment target is 60 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (92% lower). The trial reports 15 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05280314, a Phase 2 study of Melanoma and Squamous Cell Carcinoma of Head and Neck, is actively recruiting participants, sponsored by IO Biotech.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
15
Study locations

Study Summary

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.

Conditions Studied

Melanoma Squamous Cell Carcinoma of Head and Neck

Interventions

  • DRUG IO102-IO103
  • DRUG Pembrolizumab KEYTRUDA®

Study Locations (15)

Other

  • Aarhus University Hospital - Aarhus
  • Copenhagen University Hospital Herlev - Copenhagen
  • CHRU Lille - Lille
  • Hôpital Ambroise-Paré - Paris
  • Institut Gustave Roussy - Paris
  • Universitätsklinikum Essen & Research Alliance Ruhr - Essen
  • Universität Heidelberg, Medizinische Fakultät - Heidelberg
  • Hospital Universitario Quirón Dexeus - Barcelona
  • Hospital Universitario Ramón y Cajal - Madrid
  • Hospital Clínico Universitario de Valencia -INCLIVA - Valencia

Connecticut

  • Yale - New Haven

Massachusetts

  • Dana Farber Cancer Institute - Boston

Virginia

  • Massey Cancer Center - Richmond

New South Wales

  • Melanoma Institute Australia The Uiniversity of Sydney, and Royal North Shore Hospital - Sydney

Victoria

  • Peter MacCallum Cancer Centre - Melbourne

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-12-21
Est. Completion 2027-01
Phase Phase 2

Sponsor

IO Biotech

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05280314

The ClinicalTrials.gov registry entry for NCT05280314 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (92% lower). The listed sponsor is IO Biotech, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which IO102-IO103 is the first listed.

NCT05280314 reports 15 study locations spanning 6 distinct geographic areas - top geographies include Other, Connecticut, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05280314 about?

NCT05280314 is a clinical study titled "Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors". This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indicati...

What is the current status of trial NCT05280314?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-12-21. Estimated completion is 2027-01.

What conditions does trial NCT05280314 study?

This clinical trial studies the following conditions: Melanoma, Squamous Cell Carcinoma of Head and Neck.

What interventions are being tested in trial NCT05280314?

The interventions under investigation include: IO102-IO103 (DRUG), Pembrolizumab KEYTRUDA® (DRUG).

Who is sponsoring clinical trial NCT05280314?

This trial is sponsored by IO Biotech, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05280314 being conducted?

This trial has 15 study locations across Connecticut, Massachusetts, Virginia, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Squamous Cell Carcinoma of Head and Neck

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.